{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T08:57:57Z","timestamp":1772269077231,"version":"3.50.1"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[2001,11]]},"abstract":"<jats:p>The results of previous studies with genetically engineered mice have suggested that an intact central \u03b1<jats:sub>2B<\/jats:sub>-adrenergic receptor (\u03b1<jats:sub>2B<\/jats:sub>-AR) subtype mediates the development and maintenance of salt-induced hypertension. In the present study, we sought to further define the role of this receptor by injecting antisense oligodeoxynucleotides (AS-ODNs), targeting a selected sequence of the \u03b1<jats:sub>2B<\/jats:sub>-AR mRNA, into the lateral cerebral ventricle of rats that had undergone prior subtotal nephrectomy and dietary salt loading. Cell culture studies showed that these AS-ODNs could block \u03b1<jats:sub>2B<\/jats:sub>-AR protein generation. Before AS-ODN injection, blood pressure (BP) averaged 133\u00b15 mm Hg during the daytime and rose to 165\u00b14 mm Hg during the nighttime activity hours (<jats:italic>P<\/jats:italic>&lt;0.001 versus baseline average of 120\u00b12 mm Hg). The injection of AS-ODNs during the early afternoon prevented the BP rise and was associated with a significant fall in heart rate (from 385\u00b112 to 306\u00b115 bpm,<jats:italic>P<\/jats:italic>&lt;0.05) and symptoms of sedation that lasted for several hours, with a peak at 3 to 6 hours and full recovery by 24 hours. At that time, a second injection produced identical effects in all rats (n=9). Control rats (n=10) that received scrambled ODN injections had no changes in BP or heart rate patterns, and neither group had evidence of neurotoxicity, indicating that these effects are specifically due to translational inhibition of central \u03b1<jats:sub>2B<\/jats:sub>-AR. We conclude that a fully functional central \u03b1<jats:sub>2B<\/jats:sub>-AR is necessary for the induction of salt-dependent hypertension.<\/jats:p>","DOI":"10.1161\/hy1101.093426","type":"journal-article","created":{"date-parts":[[2007,9,28]],"date-time":"2007-09-28T18:37:17Z","timestamp":1191004637000},"page":"1075-1080","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":25,"title":["Effects of Antisense Oligodeoxynucleotide Targeting of the \u03b1<sub>2B<\/sub>-Adrenergic Receptor Messenger RNA in the Central Nervous System"],"prefix":"10.1161","volume":"38","author":[{"given":"Ekaterina","family":"Kintsurashvili","sequence":"first","affiliation":[{"name":"From the Hypertension and Atherosclerosis Section, Department of Medicine, Boston University School of Medicine, Boston, Mass."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Gavras","sequence":"additional","affiliation":[{"name":"From the Hypertension and Atherosclerosis Section, Department of Medicine, Boston University School of Medicine, Boston, Mass."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Conrado","family":"Johns","sequence":"additional","affiliation":[{"name":"From the Hypertension and Atherosclerosis Section, Department of Medicine, Boston University School of Medicine, Boston, Mass."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haralambos","family":"Gavras","sequence":"additional","affiliation":[{"name":"From the Hypertension and Atherosclerosis Section, Department of Medicine, Boston University School of Medicine, Boston, Mass."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.9.9.7601339"},{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0163-7258(95)02005-5"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)43016-X"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.273.5276.801"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.273.5276.803"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pa.33.040193.001331"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.6.3.1346768"},{"key":"e_1_3_2_8_2","first-page":"599","volume":"38","year":"1990","unstructured":"Lorenz W, Lomasney JW, Collins S, Regan JW, Caron MG, Lefkowitz RJ. Expression of three \u03b12-adrenergic receptor subtypes in rat tissues: implications for \u03b12 receptor classification. Mol Pharmacol. 1990; 38: 599\u2013603.","journal-title":"Mol Pharmacol"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0169-328X(91)90064-5"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.21.6.861"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.8.3491"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(89)90032-0"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1989.tb12005.x"},{"key":"e_1_3_2_14_2","first-page":"48","volume":"48","year":"1995","unstructured":"Link RE, Stevens MS, Kulatunga M, Scheinin M, Barsh GS, Kobilka BK. Targeted inactivation of the gene encoding the mouse \u03b12C-adrenoceptor homolog. Mol Pharmacol. 1995; 48: 48\u201355.","journal-title":"Mol Pharmacol"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.33.1.14"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.35.2.609"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.8.3102"},{"key":"e_1_3_2_18_2","first-page":"17","volume":"21","year":"1982","unstructured":"Kahn DJ, Mitrius JC, U\u2019Prichard DC. \u03b12-Adrenergic receptors in neuroblastoma\u00d7glioma hybrid cells: characterization with agonist and antagonist radioligands and relationship to adenylate cyclase. Mol Pharmacol. 1982; 21: 17\u201326.","journal-title":"Mol Pharmacol"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.29.1.374"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)52451-6"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.28.6.1064"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-3623(00)00051-3"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.32.2.311"},{"key":"e_1_3_2_24_2","first-page":"H1501","volume":"2657","year":"1993","unstructured":"Ping P, Faber JE. Characterization of \u03b1-adrenoceptor gene expression in arterial and venous smooth muscle. Am J Physiol. 1993; 2657: H1501\u2013H1509.","journal-title":"Am J Physiol"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.27.3.449"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.33.1.8"},{"key":"e_1_3_2_27_2","unstructured":"Brysch W. Assay systems and controls: evaluating the efficacy and specificity of antisense oligonucleotides.In: Brysch W Schlingensiepen K-H eds. Antisense: From Technology to Therapy. Oxford UK: Blackwell Science Ltd; 1997: 105\u2013144."},{"key":"e_1_3_2_28_2","first-page":"444","volume":"43","year":"1993","unstructured":"Kurose H, Arriza JL, Lefkowitz RJ. Characterization of \u03b12-adrenergic receptor subtype-specific antibodies. Mol Pharmacol. 1993; 43: 444\u2013450.","journal-title":"Mol Pharmacol"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(95)00180-S"},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0022-3565(24)36916-2","volume":"282","year":"1997","unstructured":"Heck DA, Bylund DB. Mechanism of down-regulation of \u03b12-adrenergic receptor subtypes. J Pharmacol Exp Ther. 1997; 282: 1219\u20131227.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0076-6879(99)14095-3"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0701520"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(98)00100-6"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118887"},{"key":"e_1_3_2_35_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-3565(24)39196-7","volume":"293","year":"2000","unstructured":"Kable JW, Murrin LC, Bylund DB. In vivo gene modification elucidates subtype-specific functions of \u03b12-adrenergic receptors. J Pharmacol Exp Ther. 2000; 293: 1\u20137.","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/hy1101.093426","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T08:37:22Z","timestamp":1737448642000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/hy1101.093426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,11]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2001,11]]}},"alternative-id":["10.1161\/hy1101.093426"],"URL":"https:\/\/doi.org\/10.1161\/hy1101.093426","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,11]]},"assertion":[{"value":"2001-04-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2001-05-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2001-11-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}